Trial Profile
An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections; Immunocompromised infections
- Focus Pharmacodynamics
- 23 Aug 2021 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 19 Apr 2019 Planned number of patients changed from 310 to 270.
- 19 Apr 2019 Planned End Date changed from 1 May 2019 to 1 Aug 2019.